Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merit Medical SystemsMMSI +2.77%83 EV-to-EBITDA is 14.73 as of Jul. 29, 2026, which is 35% below its 10-year median of 22.71. GuruFocus rates MMSI with a GF Score™ of 83/100 and a GF Value™ of $97.32 (Modestly Undervalued). Among 512 Medical Devices & Instruments companies, Merit Medical Systems ranks worse than 50.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Merit Medical Systems's enterprise value is $5,136 Mil.
Merit Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $349 Mil. Therefore, Merit Medical Systems's EV-to-EBITDA for today is 14.73.
The historical rank and industry rank for Merit Medical Systems's EV-to-EBITDA or its related term are showing as below:
MMSI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5 Med: 22.71 Max: 43.29
Current: 14.73
During the past 13 years, the highest EV-to-EBITDA of Merit Medical Systems was 43.29. The lowest was 11.50. And the median was 22.71.
MMSI's EV-to-EBITDA is ranked worse than 50.98% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs MMSI: 14.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Merit Medical Systems (NAS:MMSI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Merit Medical Systems's PE Ratio (TTM) for today is calculated as:
Merit Medical Systems's share price for today is $80.50.
Merit Medical Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Merit Medical Systems EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Merit Medical Systems's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Merit Medical Systems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merit Medical Systems EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Merit Medical Systems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Merit Medical Systems's EV-to-EBITDA falls into.
Merit Medical Systems's current Enterprise Value is $5,136 Mil.
Merit Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $349 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merit Medical Systems (MMSI) has a EV-to-EBITDA of 14.73 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Merit Medical Systems. This is 35% below median its historical median of 22.71. Over the past decade, Merit Medical Systems' EV-to-EBITDA has ranged from 11.50 to 43.29. According to the industry distribution chart, Merit Medical Systems ranks #261 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 51%.
Is Merit Medical Systems' EV-to-EBITDA too high?
Merit Medical Systems' current EV-to-EBITDA of 14.73 is 35% below median its 10-year median of 22.71. Over the past 10 years, this metric has ranged from a low of 11.50 to a high of 43.29. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.25. Merit Medical Systems' value of 14.73 is 3.4% above this industry median. Based on the distribution chart, Merit Medical Systems ranks #261 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Merit Medical Systems has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Merit Medical Systems' EV-to-EBITDA compare to NVST and MMED?
According to the Medical Devices & Instruments industry distribution chart, Merit Medical Systems ranks #261 out of 512 companies for EV-to-EBITDA. This places Merit Medical Systems in the lower half of its industry. The industry median EV-to-EBITDA is 14.25. Merit Medical Systems' value of 14.73 is 3.4% above this benchmark. Historically, Merit Medical Systems' own EV-to-EBITDA has ranged from 11.50 to 43.29 over the past decade. While the company's 10-year median is 22.71 vs. the industry median of 14.25, Merit Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merit Medical Systems's current EV-to-EBITDA of 14.73 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Merit Medical Systems. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merit Medical Systems's current EV-to-EBITDA is 14.73, which is 35% below median its own 10-year median of 22.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merit Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Merit Medical Systems (MMSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $97.32, compared to a current price of $80.50 — trading 17.3% below its estimated fair value. The current EV-to-EBITDA is 14.73, which is 35% below median its 10-year median of 22.71 and 3.4% above the Medical Devices & Instruments industry median of 14.25. Merit Medical Systems' overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Merit Medical Systems (MMSI), the current EV-to-EBITDA is 14.73 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merit Medical Systems (MMSI) Overvalued in 2026?
Based on GuruFocus' analysis, Merit Medical Systems stock appears to be undervalued.
The current stock price of $80.50 is trading 17.3% below its estimated GF Value™ of $97.32.
GuruFocus considers Merit Medical Systems to be Modestly Undervalued.
Key valuation signals for MMSI:
EV-to-EBITDA: 14.73 (35% below median its 10-year median of 22.71)
GF Value™: $97.32 vs. price of $80.50 (17.3% below fair value)
Industry Position: 3.4% above the Medical Devices & Instruments median (#261 of 512)
No single metric tells the full story. See the MMSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
83GF Score
Get the complete analysis for MMSI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMSI has been successfully added to your 
